Sign in to continue:

Thursday, April 23rd, 2026

ValueMax Launches 6-Month Digital Securities Commercial Paper Series 012 on ADDX Exchange at 3.5% p.a

ValueMax Launches Series 012 of 6-Month Digital Securities Commercial Paper on ADDX Exchange

ValueMax Group Announces Launch of 6-Month Digital Securities Commercial Paper Series 012 on ADDX Exchange

ValueMax Group Limited (“ValueMax” or the “Company”) and its subsidiaries have announced the launch of the twelfth series of its 6-month commercial paper in digital securities (“6-month Series 012 Issuance”) under its ongoing Commercial Paper Programme (“CP Programme”). This issuance is being conducted on the ADDX Exchange, a significant step in further digitizing and broadening the reach of its debt financing initiatives.


Key Highlights of the Announcement

  • Issuance Details: The 6-month Series 012 commercial paper is priced at 3.5% per annum and will mature approximately six months from the date of issuance.
  • Fundraising Target: ValueMax expects to raise between S\$5 million and S\$25 million through this issuance, with the Board of Directors determining the final quantum.
  • Target Investors: The offer is open exclusively to accredited investors and institutional investors, in line with regulations and the Company’s capital raising strategy.
  • Digital Securities Platform: The issuance on the ADDX Exchange highlights ValueMax’s continued adoption of digital securities and fintech innovation in its capital markets activities.

Potential Price-sensitive Information for Shareholders

  • Strategic Capital Raising: The Company’s ability to raise up to S\$25 million in short-term funding reflects confidence in its creditworthiness and balance sheet strength, and may enhance liquidity for ongoing business operations. This move to digital securities markets could signal greater efficiency and reduced costs in future capital raising.
  • Interest Rate and Funding Costs: The 3.5% per annum pricing sets a benchmark for the Company’s short-term funding costs, which could impact profitability and margins if market rates move significantly.
  • Ongoing Developments: The Company has committed to making further announcements should there be any material developments concerning the CP Programme or the Series 012 Issuance. Shareholders should monitor these updates as they could affect funding costs, capital structure, and future dividend capacity.

What Investors Should Watch

  • The size of funds ultimately raised from this issuance (between S\$5 million and S\$25 million) could indicate institutional appetite for ValueMax’s credit and influence the Company’s growth plans.
  • The adoption of digital securities for short-term commercial paper could position ValueMax as a leader in integrating new financial technologies, potentially improving transparency and secondary market liquidity for its debt instruments.
  • Any significant changes in the terms of issuance, investor demand, or use of proceeds could be price sensitive and impact shareholder value.

Other Noteworthy Information

ValueMax has made it clear that this announcement is for information purposes and does not constitute an offer or invitation to subscribe for or purchase any securities. The Company cautions investors to seek professional advice and not construe this update as legal, financial, business, or tax advice.


Next Steps

The Board will continue to keep shareholders and the market informed of any material developments related to the CP Programme and the 6-month Series 012 Issuance. Investors are encouraged to monitor upcoming disclosures and consider the potential impact on the Company’s credit profile, cost of funds, and overall financial strategy.


Disclaimer: This article is for informational purposes only and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Investors are advised to consult their own professional advisors regarding any investment decisions. The information provided is based on the Company’s public announcement and may be subject to further updates or changes.


View Reborn Coffee, Inc. Historical chart here



Hills Bancorporation Files Form 8-K SEC Report for April 2, 2026 – Company Details and Compliance Information

Hills Bancorporation Announces Change in Independent Registe...

2024 Annual Report: Biotechnology Oncology Company – Targeted Therapies, ADC Strategy, Risk Factors & Financials

Immunome, Inc. 2025 Annual Report - Comprehensive Investor A...

Digimarc Corporation Announces Holding Company Reorganization Plan and Merger Agreement for Shareholder Vote in 2026

Digimarc Corporation Announces Proposed Holding Company Reor...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today